Development of an antibody cocktail for treatment of Sudan virus infection
Abstract
Ebolaviruses pose a significant threat to the global community, particularly in areas of equatorial and West Africa. While Ebola virus has caused the greatest number of human cases, Sudan virus is responsible for numerous outbreaks with equally lethal consequences. Antibody-based immunotherapies against ebolaviruses have gained prominence in recent years, resulting in the development of several Ebola virus-specific antibody cocktails, yet no Sudan virus-specific cocktails exist. In collaboration with industry partners, we generated a library of human chimeric monoclonal antibodies (mAbs) specific for the glycoprotein of Sudan virus. Through a series of in vitro assays and rodent efficacy studies, we down-selected a lead mAb cocktail that demonstrated protective efficacy in a nonhuman primate model of Sudan virus infection.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 03, 2020
- Source ID
- 10.1073/pnas.1914985117
Entities
People
- Ana I. Kuehne
- Andrew S Herbert
- Anna Z Wec
- Brian Green
- Danielle E. Dorosky
- Darryl Sampey
- Do H. Kim
- Jeffery W. Froude
- Jesus Velasco
- John M Dye
- Kartik Chandran
- Kevin J Whaley
- Konstantin Musiychuk
- Larry Zeitlin
- Michael H. Pauly
- Natasha Bohorova
- Nicole M. Josleyn
- Ognian Bohorov
- R. Mark Jones
- Ramon A. Ortiz
- Russell R. Bakken
- Samantha E. Zak
- Spencer W Stonier
- Stephen J. Streatfield
- Vidadi Yusibov
- Zachary A. Bornholdt
Organizations
- Albert Einstein College of Medicine
- Defense Threat Reduction Agency
- Geneva Foundation
- National Institute of Allergy and Infectious Diseases